Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
  • Novartis AG NVS is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG RHHBY, triggering speculation about where the Company will spend the money. 
  • Another significant acquisition could be next. Alnylam Pharmaceuticals Inc ALNY is a prime potential buyout target for Novartis, Bloomberg reported, citing people with knowledge of the matter.
  • Alnylam is the developer of the RNA interference (RNAi) technology behind Novartis' newly acquired cholesterol drug Leqvio (inclisiran).
  • The revelation follows Novo Nordisk A/S's NVO announcement that it is shelling out $3.3 billion to purchase clinical-stage RNAi biotech Dicerna Pharmaceuticals Inc DRNA.
  • The report added that Vertex Pharmaceuticals Inc VRTXIntellia Therapeutics Inc NTLA, Biogen Inc BIIBIncyte Corp INCY, and BioMarin Pharmaceutical Inc BMRN are among a range of other companies seen as potential targets.
  • Also Read: Novartis Mulls Strategic Options For Sandoz, Reaffirms FY21 Outlook.
  • Price Action: ALNY shares are up 4.60% at $180.68 during the market session on the last check Thursday.

Posted In: BriefsBiotechLong IdeasM&ANewsHealth CareRumorsMoversTrading IdeasGeneral